TICKERNOMICS Sign up
Last Update: 2024-12-27 15:26:30
AC Immune SA ( ACIU ) https://www.acimmune.com
2.71USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
Switzerland
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-44.11%
ACIU
SPY
32.66%
-47.98%
ACIU
SPY
108.59%
-67.76%
ACIU
SPY
302.52%
ACIU
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
270.30
82.40
0.04
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.27
5.86
1.74
36.35
0.00
-2.79
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
28.52
100.00
-50.59
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.3312
-24.38
-16.39
1.09
Other Earnings and Cash Flow Stats:
AC Immune SA ( ACIU ) Net Income TTM ($MM) is -51.33
AC Immune SA ( ACIU ) Operating Income TTM ($MM) is -43.91
AC Immune SA ( ACIU ) Owners' Earnings Annual ($MM) is 0.00
AC Immune SA ( ACIU ) Current Price to Owners' Earnings ratio is 0.00
AC Immune SA ( ACIU ) EBITDA TTM ($MM) is -41.45
AC Immune SA ( ACIU ) EBITDA Margin is -50.59%
Capital Allocation:
AC Immune SA ( ACIU ) has paid 0.00 dividends per share and bought back -16.143429 million shares in the past 12 months
AC Immune SA ( ACIU ) has increased its debt by 0.0 million USD in the last 12 months
Capital Structure:
AC Immune SA ( ACIU ) Interest-bearing Debt ($MM) as of last quarter is 0
AC Immune SA ( ACIU ) Annual Working Capital Investments ($MM) are 27
AC Immune SA ( ACIU ) Book Value ($MM) as of last quarter is 154
AC Immune SA ( ACIU ) Debt/Capital as of last quarter is 0%
Other Balance Sheet Stats:
AC Immune SA ( ACIU ) has 38 million in cash on hand as of last quarter
AC Immune SA ( ACIU ) has 120 million of liabilities due within 12 months, and long term debt 0 as of last quarter
AC Immune SA ( ACIU ) has 100 common shares outstanding as of last quarter
AC Immune SA ( ACIU ) has 0 million USD of preferred stock value
Academic Scores:
AC Immune SA ( ACIU ) Altman Z-Score is -0.54 as of last quarter
AC Immune SA ( ACIU ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
AC Immune SA ( ACIU ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of AC Immune SA ( ACIU ) for the amount of $ on
25.98% of AC Immune SA ( ACIU ) is held by insiders, and 34.29% is held by institutions
AC Immune SA ( ACIU ) went public on 2016-09-23
Other AC Immune SA ( ACIU ) financial metrics:
FCF:133.72
Unlevered Free Cash Flow:0.00
EPS:0.24
Operating Margin:28.52
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:15.82
Beta:1.09
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About AC Immune SA ( ACIU ) :
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.